Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
Advertisement
Emily MenendezProstate Cancer Diagnostics | June 25, 2025
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Read More
Jessica GangaProstate Cancer Diagnostics | June 25, 2025
Researchers investigated the use of PSMA PET-CT to determine treatment options for patients with biochemical failure in PC.
Emily MenendezProstate Cancer Diagnostics | June 25, 2025
18F-fluciclovine PET detected disease in more than half of the study’s patients with BCR and negative PSMA PET results.
Emily MenendezProstate Cancer Diagnostics | May 15, 2025
The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Carissa Chu, MDProstate Cancer Diagnostics | June 25, 2025
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Thomas Hope, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Wolfgang Fendler, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.
Jérémie Calais, MD, PhDRLT | March 26, 2025
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Louise Emmett, MDProstate Cancer Diagnostics | March 24, 2025
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Emily MenendezProstate Cancer Diagnostics | March 13, 2025
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Emily MenendezProstate Cancer Diagnostics | January 28, 2025
Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.
Jacob Ark, MDCRPC | February 3, 2025
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
Brandon TwyfordProstate Cancer Diagnostics | January 24, 2025
The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.
Rafael Sanchez-Salas, MDLocalized | January 21, 2025
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Jihad Kaouk, MDLocalized | January 21, 2025
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Ian Thompson, Jr., MDLocalized | January 21, 2025
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Advertisement
Advertisement